Ribociclib, sold under the brand name Kisqali, is a medication used for the treatment of certain kinds of breast cancer. Ribociclib is a kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. Technically, ribociclib is a selective inhibitor of cyclin dependent kinases 4 and 6, blocking phosphorylation of retinoblastoma protein and arresting cell cycle progression at the G1 phase; the approved clinical regimen for hormone receptor positive, HER2 negative advanced or metastatic breast cancer is oral ribociclib in combination with endocrine therapy, typically administered as 600 mg once daily for 21 days followed by 7 days off per 28 day cycle, with dose adjustments for toxicity and for interactions with strong CYP3A modulators; absorption is sufficient for oral dosing, the drug is primarily metabolized by CYP3A4, and clinically important laboratory and ECG monitoring includes neutrophil counts and QT interval assessment.
Parent: Ribociclib
Parent: Ribociclib
Parent: Ribociclib
Parent: Ribociclib
Parent: Ribociclib
![7-cyclopentyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid](https://veeprho.com/wp-content/uploads/2026/04/7-cyclopentyl-2-5-4-nitrosopiperazin-1-ylpyridin-2-ylamino-7H-pyrrolo23-dpyrimidine-6-carboxylic-acid-NA-VE0028665.png "7-cyclopentyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid")
Parent: Ribociclib
![7-cyclopentyl-2-hydroxy N,N-dimethyl-7H pyrrolo[2,3-d]pyrimidine-6- carboxamide](https://veeprho.com/wp-content/uploads/2026/05/7-cyclopentyl-2-hydroxy-NN-dimethyl-7H-pyrrolo23-dpyrimidine-6-carboxamide-NA-VE0028834.png "7-cyclopentyl-2-hydroxy N,N-dimethyl-7H pyrrolo[2,3-d]pyrimidine-6- carboxamide")
Parent: Ribociclib
API impurity control for ribociclib is normally defined in the drug substance specification and stability plans and typically distinguishes process related impurities, degradation products and residual solvents; a representative specification framework used by manufacturers and accepted in regulatory dossiers often sets limits such as individual identified impurities controlled in the range of 0.1 percent to 0.5 percent, unspecified impurities limited to 0.05 percent to 0.10 percent, and total impurities typically limited to about 1.0 percent to 2.0 percent, with tighter limits applied to genotoxic or toxicologically concerning species and specific identification and control of known related compounds from the synthetic route such as demethylated, dealkylated or N-oxide variants; exact numerical limits and impurity identities are established case by case in the master batch record and regulatory submission based on toxicity qualification and ICH Q3 guidance.
No, Ribociclib is not traditional cytotoxic chemotherapy; it is a targeted small molecule inhibitor of CDK4 and CDK6 that interferes with cell cycle signaling and is used together with endocrine therapy for certain hormone receptor positive breast cancers.
Common adverse effects include neutropenia, leukopenia, anemia, fatigue, nausea, diarrhea, and elevated liver enzymes; less common but clinically important effects include QT interval prolongation, hepatotoxicity and interstitial lung disease, so regular blood counts, liver function tests and ECG monitoring are recommended during treatment.
Duration depends on disease response and tolerability; in metastatic settings ribociclib is typically continued until disease progression or unacceptable toxicity, whereas in adjuvant or trial settings duration may be defined by the study protocol; standard metastatic dosing cycles are repeated every 28 days with clinical review and safety monitoring between cycles.
Comparison depends on clinical context; for hormone receptor positive, HER2 negative advanced breast cancer, ribociclib combined with endocrine therapy has demonstrated progression free survival benefit versus endocrine therapy alone and is generally preferred over single agent cytotoxic chemotherapy in patients for whom endocrine options remain appropriate because it provides disease control with a different safety profile, but direct comparison to chemotherapy varies by patient characteristics, disease burden and treatment goals and should be determined by treating oncology specialists.
